Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis

Martins, Diana Mafalda Miranda; Matos, Cristiano; Joaquim, João José Morais,  1969-

http://hdl.handle.net/10400.26/15532

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Diana Martins [ISoP 2015_Drug Safety].pdf		144.06 KB	Adobe PDF	Download

Send Feedback

Authors

Martins, Diana Mafalda Miranda

Matos, Cristiano

Joaquim, João José Morais, 1969-

Abstract(s)

Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families. This disease is characterized by relapses or exacerbations, which are clinical consequences of increased inflammatory activity in the CNS. Few treatment options for patients with secondary progressive multiple sclerosis (SPMS) is available. Mitoxantrone (type II topoisomerase inhibitor) could be used to treat MS, most notably the subset known as SPMS. Mitoxantrone will not cure MS, but could be effective in slowing the progression of SPMS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS.

Keywords

Mitoxantrona Cardiotoxicidade Esclerose múltipla Terapêutica Farmácia

URI

http://hdl.handle.net/10400.26/15532

Citation

Martins, Diana Mafalda Miranda; Matos, Cristiano; Joaquim, João José. Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis, Trabalho apresentado em 15th ISoP Annual Meeting ‘‘Cubism in Pharmacovigilance’’ , In 15th ISoP Annual Meeting ‘‘Cubism in Pharmacovigilance’’ - Abstracts, Praga, 2015.